Bedrijfsoverzicht
ETHZilla Corporation is a technology firm dedicated to developing Ethereum-based infrastructure specifically designed for the tokenization of real-world assets, enabling the conversion of illiquid, institutional-grade assets into blockchain-based financial instruments via Ethereum Layer 2 solutions. The company operates within the healthcare sector, specifically classified under the biotechnology industry, which typically involves high capital expenditure and significant research phases before commercialization, although this specific entity focuses on digital asset infrastructure. According to available data, the company possesses a market capitalization of $68.63 million and reports annual revenue of $4.11 million based on trailing twelve-month figures, while the specific count of employees is not disclosed in the current dataset. These valuation and revenue metrics indicate that ETHZilla Corporation is a small-cap entity operating with a relatively modest revenue base, suggesting it is in an early-stage growth phase where market value is driven more by potential technological adoption than by substantial current earnings generation.
Financiële gezondheid
The financial performance of ETHZilla Corporation shows a trailing twelve-month revenue of $4.11 million, contrasted sharply by a net income of -$224,528,976 and an EBITDA of -$226,656,496, revealing a significant gap between top-line sales and bottom-line profitability. This substantial divergence indicates a highly aggressive cost structure or high burn rate, where operating expenses vastly exceed the revenue generated, resulting in a net loss that is disproportionate to the reported sales volume. The company generated free cash flow of -$441,101,376, which highlights a severe lack of financial flexibility and a heavy reliance on external capital sources to sustain operations without positive cash generation from its core activities. Margin analysis further underscores these challenges, with a gross margin of 100.0% suggesting that the cost of goods sold is negligible or non-existent for this period, yet the operating margin stands at -5364.6% and the profit margin at 0.0%, reflecting extreme inefficiencies or one-time costs that have eroded all operational profits. On the balance sheet side, ETHZilla holds $53.31 million in cash but carries a total debt load of $546.76 million, creating a precarious liquidity position supported by a debt-to-equity ratio of 122.83, which classifies the company as highly leveraged rather than conservative. Despite the high leverage, the current ratio is reported at 10.07, indicating that the company technically possesses more than ten times the current assets relative to current liabilities, though the quality of those assets in covering the massive debt burden remains a critical concern. Return metrics illustrate the impact of these financial conditions, with a return on equity of -96.5% and a return on assets of -27.8%, demonstrating that management has been ineffective at generating value for shareholders or utilizing the company's asset base to produce positive returns.
Waarderingsbeoordeling
Valuation metrics for ETHZilla Corporation present significant anomalies, as the trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's lack of positive earnings over the trailing twelve months and likely expected future earnings. The absence of a positive P/E implies that traditional earnings-based valuation models are inapplicable, and investors must rely on alternative metrics to assess the company's worth relative to its market capitalization of $68.63 million. The price-to-book ratio is recorded at 0.13, indicating that the company's market value is trading at a significant discount to its book value, which often occurs in distressed biotechnology firms or those facing severe financial distress. Additionally, the price-to-sales ratio stands at 16.70 while the EV/EBITDA is -2.52, suggesting that the market is pricing the company based on revenue potential or strategic asset value rather than profitability, and the negative EV/EBITDA reflects the overwhelming debt burden relative to earnings power. Regarding price volatility, the stock has a 52-week high of $174.60 and a 52-week low of $2.99, meaning the current trading price sits significantly below the 52-week high, specifically reflecting a position that is more than 98% below the recent peak and well above the absolute floor of the trading range. The stock exhibits a beta of 1.14, which indicates that the share price is expected to be 14% more volatile than the broader market, exposing shareholders to amplified swings during periods of market turbulence.
Growth & Income
Growth metrics for ETHZilla Corporation show revenue growth year-over-year and earnings growth year-over-year both listed as N/A, preventing a direct comparison of earnings expansion relative to revenue expansion within the current reporting period. Since the company does not pay dividends, the dividend yield and payout ratio are both N/A and 0.0% respectively, indicating that the company retains all generated cash or utilizes reserves to fund operations rather than distributing income to shareholders. Consequently, the company's capital allocation strategy focuses entirely on reinvesting earnings into its technology infrastructure and blockchain development efforts rather than providing an income stream for investors. The overall growth and income profile is characterized by a lack of historical growth data and a complete absence of dividend income, reflecting the speculative nature of the stock where value accrual is entirely dependent on future operational success and the successful commercialization of its tokenization platforms.